drugset / Trial / NCT01455103
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate pharmacodynamic changes of BMS-936559 treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with unresectable Stage III or IV Melanoma.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-936559 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 10 mg/kg | Intravenous |